Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Update

Artelo Biosciences, Inc. (NASDAQ:ARTL) was the target of a significant growth in short interest in January. As of January 15th, there was short interest totaling 124,020 shares, a growth of 153.3% from the December 31st total of 48,967 shares. Based on an average daily trading volume, of 135,794 shares, the days-to-cover ratio is presently 0.9 days. Currently, 6.9% of the company’s stock are sold short. Currently, 6.9% of the company’s stock are sold short. Based on an average daily trading volume, of 135,794 shares, the days-to-cover ratio is presently 0.9 days.

Artelo Biosciences Stock Up 1.8%

Artelo Biosciences stock traded up $0.03 during mid-day trading on Friday, hitting $1.71. 24,078 shares of the company’s stock traded hands, compared to its average volume of 86,803. The firm has a 50 day moving average price of $1.64 and a 200 day moving average price of $4.95. The company has a market cap of $3.45 million, a PE ratio of -0.08 and a beta of 1.04. Artelo Biosciences has a one year low of $1.15 and a one year high of $28.60.

Artelo Biosciences (NASDAQ:ARTL) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($3.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($3.15). On average, analysts expect that Artelo Biosciences will post -2.62 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ARTL has been the topic of several research analyst reports. Maxim Group reaffirmed a “hold” rating on shares of Artelo Biosciences in a research report on Wednesday, November 19th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Artelo Biosciences in a report on Monday, December 29th. One research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $24.00.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes.

The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia.